Clinical Cancer Research
AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.
Clinical Cancer Research appears twice a month and is the main venue for phase 1 trials of new oncology drugs, translational biomarker and pharmacokinetic analyses, and the FDA Oncology Center of Excellence approval summaries that explain the evidence behind each new indication. Hybrid access; free after 12 months.
Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.
Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.
Neurosurgeon who delivers CAR-T cells directly into the brain in City of Hope's glioma trials.
RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.
Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.
Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.
Has led AACR for more than four decades, growing it into the world's largest cancer research society.
Lung cancer oncologist who showed plasma genotyping matches tissue and leads Canadian lung trials.
Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.
Ruth Plummer is an early-phase trialist who ran the first-in-human study of a PARP inhibitor.